<DOC>
	<DOC>NCT01777282</DOC>
	<brief_summary>This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This study is designed to examine the long term safety and efficacy of weekly subcutaneously injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in Japanese subjects with type 2 diabetes mellitus. Subjects with a historical diagnosis of type 2 diabetes mellitus who are inadequately controlled on a single oral antidiabetic agent will be recruited into the study. Subjects will continue on their single antidiabetic agent and once weekly albiglutide will be added.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Subjects with diagnosis of Type 2 Diabetes Mellitus, who are experiencing inadequate glycemic control and receiving treatment with a stable dose of a single oral antidiabetic medication Body mass index (BMI) 17 to 40 kg/ m2 inclusive Subjects with an HbA1c between 7.0% and 10.0% at Screening Creatinine clearance &gt;30 mL/min (calculated using the CockcroftGault formula) History of type 1 diabetes mellitus Female subject is pregnant, lactating, or &lt;6 weeks postpartum Clinically significant cardiovascular and/or cerebrovascular disease Current ongoing symptomatic biliary disease, clinical signs or symptoms of pancreatitis, or a history of chronic or acute pancreatitis, as determined by the investigator Serum amylase &gt;=3 ×ULN and/or serum lipase &gt;=2 × ULN and/or subject is experiencing any symptoms possibly related to pancreatitis Prior use of a GLP1R agonist or DPPIV inhibitor within 6 months before Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>albiglutide</keyword>
	<keyword>Japanese</keyword>
	<keyword>glucagon-like peptide-1</keyword>
	<keyword>GSK716155</keyword>
</DOC>